A detailed history of Baldwin Brothers LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Baldwin Brothers LLC holds 8,997 shares of VRTX stock, worth $4.52 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares
8,997
Previous 8,986 0.12%
Holding current value
$4.52 Million
Previous $4.21 Million 0.64%
% of portfolio
0.29%
Previous 0.33%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$460.0 - $505.78 $5,060 - $5,563
11 Added 0.12%
8,997 $4.18 Million
Q2 2024

Jul 12, 2024

BUY
$392.81 - $485.53 $1,571 - $1,942
4 Added 0.04%
8,986 $4.21 Million
Q1 2024

Apr 12, 2024

SELL
$407.69 - $446.08 $77,461 - $84,755
-190 Reduced 2.07%
8,982 $3.75 Million
Q4 2023

Jan 08, 2024

BUY
$343.0 - $410.68 $12,005 - $14,373
35 Added 0.38%
9,172 $3.73 Million
Q3 2023

Oct 10, 2023

SELL
$338.18 - $362.46 $84,545 - $90,615
-250 Reduced 2.66%
9,137 $3.18 Million
Q4 2022

Jan 27, 2023

BUY
$285.76 - $321.48 $2.66 Million - $2.99 Million
9,312 Added 12416.0%
9,387 $0
Q4 2019

Jan 29, 2020

SELL
$166.71 - $223.91 $666 - $895
-4 Reduced 5.06%
75 $16,000
Q3 2019

Oct 10, 2019

SELL
$166.23 - $187.09 $152,599 - $171,748
-918 Reduced 92.08%
79 $14,000
Q2 2019

Jul 19, 2019

SELL
$164.61 - $190.37 $37,201 - $43,023
-226 Reduced 18.48%
997 $183,000
Q3 2018

Oct 26, 2018

SELL
$167.73 - $192.74 $13,586 - $15,611
-81 Reduced 6.21%
1,223 $235,000
Q1 2018

Apr 16, 2018

BUY
$151.6 - $177.13 $11,370 - $13,284
75 Added 6.1%
1,304 $213,000
Q4 2017

Jan 24, 2018

BUY
$137.28 - $155.55 $168,717 - $191,170
1,229
1,229 $184,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Baldwin Brothers LLC Portfolio

Follow Baldwin Brothers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baldwin Brothers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Baldwin Brothers LLC with notifications on news.